Comparison between atorvastatin and rosuvastatin in renal function decline among patients with diabetes

Eugene Han, Gyuri Kim, Ji Yeon Lee, Yong Ho Lee, Beom Seok Kim, Byung Wan Lee, Bong Soo Cha, Eun Seok Kang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Although the beneficial effects of statin treatment in dyslipidemia and atherosclerosis have been well studied, there is limited information regarding the renal effects of statins in diabetic nephropathy. We aimed to investigate whether, and which, statins affected renal function in Asian patients with diabetes. Methods: We enrolled 484 patients with diabetes who received statin treatment for more than 12 months. We included patients treated with moderate-intensity dose statin treatment (atorvastatin 10 to 20 mg/day or rosuvastatin 5 to 10 mg/day). The primary outcome was a change in estimated glomerular filtration rate (eGFR) during the 12-month statin treatment, and rapid renal decline was defined as a > 3% reduction in eGFR in a 1-year period. Results: In both statin treatment groups, patients showed improved serum lipid levels and significantly reduced eGFRs (from 80.3 to 78.8 mL/min/1.73 m2 for atorvastatin [P=0.012], from 79.1 to 76.1 mL/min/1.73 m2 for rosuvastatin [P=0.001]). A more rapid eGFR decline was observed in the rosuvastatin group than in the atorvastatin group (48.7% vs. 38.6%, P=0.029). Multiple logistic regression analyses demonstrated more rapid renal function loss in the rosuvastatin group than in the atorvastatin group after adjustment for other confounding factors (odds ratio, 1.60; 95% confidence interval, 1.06 to 2.42). Conclusion: These results suggest that a moderate-intensity dose of atorvastatin has fewer detrimental effects on renal function than that of rosuvastatin.

Original languageEnglish
Pages (from-to)274-280
Number of pages7
JournalEndocrinology and Metabolism
Volume32
Issue number2
DOIs
Publication statusPublished - 2017 Jun 1

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Kidney
Glomerular Filtration Rate
Therapeutics
Diabetic Nephropathies
Dyslipidemias
Atorvastatin Calcium
Rosuvastatin Calcium
Atherosclerosis
Logistic Models
Odds Ratio
Regression Analysis
Confidence Intervals
Lipids
Serum

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Han, Eugene ; Kim, Gyuri ; Lee, Ji Yeon ; Lee, Yong Ho ; Kim, Beom Seok ; Lee, Byung Wan ; Cha, Bong Soo ; Kang, Eun Seok. / Comparison between atorvastatin and rosuvastatin in renal function decline among patients with diabetes. In: Endocrinology and Metabolism. 2017 ; Vol. 32, No. 2. pp. 274-280.
@article{a25183954121464c8bde1cedc8c0d5e9,
title = "Comparison between atorvastatin and rosuvastatin in renal function decline among patients with diabetes",
abstract = "Background: Although the beneficial effects of statin treatment in dyslipidemia and atherosclerosis have been well studied, there is limited information regarding the renal effects of statins in diabetic nephropathy. We aimed to investigate whether, and which, statins affected renal function in Asian patients with diabetes. Methods: We enrolled 484 patients with diabetes who received statin treatment for more than 12 months. We included patients treated with moderate-intensity dose statin treatment (atorvastatin 10 to 20 mg/day or rosuvastatin 5 to 10 mg/day). The primary outcome was a change in estimated glomerular filtration rate (eGFR) during the 12-month statin treatment, and rapid renal decline was defined as a > 3{\%} reduction in eGFR in a 1-year period. Results: In both statin treatment groups, patients showed improved serum lipid levels and significantly reduced eGFRs (from 80.3 to 78.8 mL/min/1.73 m2 for atorvastatin [P=0.012], from 79.1 to 76.1 mL/min/1.73 m2 for rosuvastatin [P=0.001]). A more rapid eGFR decline was observed in the rosuvastatin group than in the atorvastatin group (48.7{\%} vs. 38.6{\%}, P=0.029). Multiple logistic regression analyses demonstrated more rapid renal function loss in the rosuvastatin group than in the atorvastatin group after adjustment for other confounding factors (odds ratio, 1.60; 95{\%} confidence interval, 1.06 to 2.42). Conclusion: These results suggest that a moderate-intensity dose of atorvastatin has fewer detrimental effects on renal function than that of rosuvastatin.",
author = "Eugene Han and Gyuri Kim and Lee, {Ji Yeon} and Lee, {Yong Ho} and Kim, {Beom Seok} and Lee, {Byung Wan} and Cha, {Bong Soo} and Kang, {Eun Seok}",
year = "2017",
month = "6",
day = "1",
doi = "10.3803/EnM.2017.32.2.274",
language = "English",
volume = "32",
pages = "274--280",
journal = "Endocrinology and Metabolism",
issn = "2093-596X",
publisher = "Korean Endocrine Society",
number = "2",

}

Comparison between atorvastatin and rosuvastatin in renal function decline among patients with diabetes. / Han, Eugene; Kim, Gyuri; Lee, Ji Yeon; Lee, Yong Ho; Kim, Beom Seok; Lee, Byung Wan; Cha, Bong Soo; Kang, Eun Seok.

In: Endocrinology and Metabolism, Vol. 32, No. 2, 01.06.2017, p. 274-280.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison between atorvastatin and rosuvastatin in renal function decline among patients with diabetes

AU - Han, Eugene

AU - Kim, Gyuri

AU - Lee, Ji Yeon

AU - Lee, Yong Ho

AU - Kim, Beom Seok

AU - Lee, Byung Wan

AU - Cha, Bong Soo

AU - Kang, Eun Seok

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Background: Although the beneficial effects of statin treatment in dyslipidemia and atherosclerosis have been well studied, there is limited information regarding the renal effects of statins in diabetic nephropathy. We aimed to investigate whether, and which, statins affected renal function in Asian patients with diabetes. Methods: We enrolled 484 patients with diabetes who received statin treatment for more than 12 months. We included patients treated with moderate-intensity dose statin treatment (atorvastatin 10 to 20 mg/day or rosuvastatin 5 to 10 mg/day). The primary outcome was a change in estimated glomerular filtration rate (eGFR) during the 12-month statin treatment, and rapid renal decline was defined as a > 3% reduction in eGFR in a 1-year period. Results: In both statin treatment groups, patients showed improved serum lipid levels and significantly reduced eGFRs (from 80.3 to 78.8 mL/min/1.73 m2 for atorvastatin [P=0.012], from 79.1 to 76.1 mL/min/1.73 m2 for rosuvastatin [P=0.001]). A more rapid eGFR decline was observed in the rosuvastatin group than in the atorvastatin group (48.7% vs. 38.6%, P=0.029). Multiple logistic regression analyses demonstrated more rapid renal function loss in the rosuvastatin group than in the atorvastatin group after adjustment for other confounding factors (odds ratio, 1.60; 95% confidence interval, 1.06 to 2.42). Conclusion: These results suggest that a moderate-intensity dose of atorvastatin has fewer detrimental effects on renal function than that of rosuvastatin.

AB - Background: Although the beneficial effects of statin treatment in dyslipidemia and atherosclerosis have been well studied, there is limited information regarding the renal effects of statins in diabetic nephropathy. We aimed to investigate whether, and which, statins affected renal function in Asian patients with diabetes. Methods: We enrolled 484 patients with diabetes who received statin treatment for more than 12 months. We included patients treated with moderate-intensity dose statin treatment (atorvastatin 10 to 20 mg/day or rosuvastatin 5 to 10 mg/day). The primary outcome was a change in estimated glomerular filtration rate (eGFR) during the 12-month statin treatment, and rapid renal decline was defined as a > 3% reduction in eGFR in a 1-year period. Results: In both statin treatment groups, patients showed improved serum lipid levels and significantly reduced eGFRs (from 80.3 to 78.8 mL/min/1.73 m2 for atorvastatin [P=0.012], from 79.1 to 76.1 mL/min/1.73 m2 for rosuvastatin [P=0.001]). A more rapid eGFR decline was observed in the rosuvastatin group than in the atorvastatin group (48.7% vs. 38.6%, P=0.029). Multiple logistic regression analyses demonstrated more rapid renal function loss in the rosuvastatin group than in the atorvastatin group after adjustment for other confounding factors (odds ratio, 1.60; 95% confidence interval, 1.06 to 2.42). Conclusion: These results suggest that a moderate-intensity dose of atorvastatin has fewer detrimental effects on renal function than that of rosuvastatin.

UR - http://www.scopus.com/inward/record.url?scp=85023183663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023183663&partnerID=8YFLogxK

U2 - 10.3803/EnM.2017.32.2.274

DO - 10.3803/EnM.2017.32.2.274

M3 - Article

AN - SCOPUS:85023183663

VL - 32

SP - 274

EP - 280

JO - Endocrinology and Metabolism

JF - Endocrinology and Metabolism

SN - 2093-596X

IS - 2

ER -